Aurobindo now launching Esomeprazole Magnesium Delayed-release Capsules USP, 20 mg and 40 mg

East Windsor, N.J. – Aurobindo Pharma USA has launched Esomeprazole Magnesium Delayed-release (DR) Capsules USP, 20 mg and 40 mg into the marketplace. The product is therapeutically equivalent to the reference listed drug (RLD), NEXIUM® of AstraZeneca Pharmaceuticals LP.

Esomeprazole Magnesium DR Capsules 20 mg and 40 mg is indicated for the treatment of gastroesophageal reflux disease (GERD) and risk reduction of NSAID-associated gastric ulcer.

Esomeprazole Magnesium DR Capsules 20 mg and 40 mg represents the latest addition to Aurobindo’s broad line of vertically integrated generic pharmaceuticals.